Actively Recruiting
Hepatoprotective Effects of Reishi Mushroom- (Ganoderma Lucidum) Among Metabolic Dysfunction-associated Fatty Liver Disease Patients
Led by University of Lahore · Updated on 2026-04-16
102
Participants Needed
1
Research Sites
27 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This 12-week RCT investigates the hepatoprotective and immunomodulatory effects of Ganoderma lucidum combined with a probiotic-rich diet in adults with MAFLD, assessing liver enzymes, lipid profile, inflammation, gut microbiota, and oxidative stress. Findings are expected to show dose-dependent improvements in hepatic fat, insulin resistance, and inflammatory markers, potentially reducing reliance on pharmacotherapy in
CONDITIONS
Official Title
Hepatoprotective Effects of Reishi Mushroom- (Ganoderma Lucidum) Among Metabolic Dysfunction-associated Fatty Liver Disease Patients
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Adults aged 35-65 years
- BMI between 18.5 and 30 kg/m²
- Complete blood count within specified ranges (WBC 4,000-11,000 cells/μL; RBC men 4.5-6.0 million/μL, women 4.0-5.5 million/μL; hemoglobin men 13.5-17.5 g/dL, women 12.0-15.5 g/dL; platelets 150,000-450,000 cells/μL)
- Lipid profile markers showing elevated LDL, total cholesterol, or triglycerides below 150 mg/dL or between 200-499 mg/dL
- Liver function test markers ALT > 56 U/L, AST > 40 U/L, ALP > 147 U/L
- Elevated inflammatory markers (CRP > 3 mg/L, IL-6 ≥ 3 pg/mL, TNF-α ≥ 8 pg/mL)
- Elevated blood sugar levels (fasting above 126 mg/dL or post-meal above 200 mg/dL)
You will not qualify if you...
- Diagnosed with severe cardiovascular disease, liver failure, or kidney impairment
- Pregnant or breastfeeding women
- Currently using statins, ezetimibe, PCSK9 inhibitors, or other lipid-lowering therapies
- Allergic to mushrooms
- Diagnosed with celiac disease or other chronic gastrointestinal disorders such as Crohn's disease or ulcerative colitis
- History of cancer
- Participated in another clinical trial within the last 3 months
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Sana Noreen
Lahore, Pakistan, 54000
Actively Recruiting
Research Team
S
Sana Noreen, PhD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
SINGLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
SUPPORTIVE_CARE
Number of Arms
3
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here